No connection

Search Results

AMWL vs GOSS

AMWL
American Well Corporation
BEARISH
Price
$4.87
Market Cap
$79.7M
Sector
Healthcare
AI Confidence
88%
GOSS
Gossamer Bio, Inc.
BEARISH
Price
$0.37
Market Cap
$87.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AMWL
--
GOSS
--
Forward P/E
AMWL
-1.0
GOSS
-2.23
P/B Ratio
AMWL
0.31
GOSS
-0.71
P/S Ratio
AMWL
0.3
GOSS
1.8
EV/EBITDA
AMWL
1.51
GOSS
-0.94

Profitability

Gross Margin
AMWL
52.59%
GOSS
100.0%
Operating Margin
AMWL
-52.11%
GOSS
-333.65%
Profit Margin
AMWL
-42.8%
GOSS
0.0%
ROE
AMWL
-37.05%
GOSS
--
ROA
AMWL
-15.13%
GOSS
-41.86%

Growth

Revenue Growth
AMWL
-7.8%
GOSS
47.1%
Earnings Growth
AMWL
--
GOSS
--

Financial Health

Debt/Equity
AMWL
0.02
GOSS
--
Current Ratio
AMWL
3.13
GOSS
2.64
Quick Ratio
AMWL
2.96
GOSS
2.36

Dividends

Dividend Yield
AMWL
--
GOSS
--
Payout Ratio
AMWL
0.0%
GOSS
0.0%

AI Verdict

AMWL BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a low Price/Book and Price/Sales ratio suggesting potential value, persistent unprofitability, negative earnings momentum, and deteriorating revenue growth paint a bleak picture. Insider selling activity and a lack of analyst consensus further undermine confidence, while the company's long-term price performance has been catastrophic, down 99.3% over five years. Although the balance sheet shows low leverage and strong liquidity, these are overshadowed by systemic profitability and growth failures.

Strengths
Strong liquidity position with Current Ratio of 3.13 and Quick Ratio of 2.96 provides short-term financial flexibility.
Low Debt/Equity ratio of 0.02 indicates minimal reliance on debt financing and low financial risk from leverage.
Gross Margin of 52.59% reflects pricing power or efficient cost control at the production level.
Risks
Critically low Piotroski F-Score of 1/9 signals widespread financial weakness across profitability, leverage, and operating efficiency.
Persistent unprofitability with Profit Margin of -42.80% and ROE of -37.05% eroding shareholder value.
Revenue declining YoY by 7.80%, indicating shrinking top-line and potential loss of market relevance.
GOSS BEARISH

GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.

Strengths
Strong YoY revenue growth of 47.10%
Healthy short-term liquidity with a Current Ratio of 2.64
Quick Ratio of 2.36 suggests immediate obligations can be met
Risks
Negative Book Value (P/B -0.71) indicating liabilities exceed assets
Piotroski F-Score of 0/9 signals severe fundamental deterioration
Extreme price decay with a 5-year decline of 95.6%

Compare Another Pair

AMWL vs GOSS: Head-to-Head Comparison

This page compares American Well Corporation (AMWL) and Gossamer Bio, Inc. (GOSS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile